Skip to main content
logo
CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
57.72
-1.65 (-2.78%)
At close: Aug 28, 2026, 4:00 PM EDT
56.85
-0.87 (-1.51%)
Pre-market: Aug 31, 2026, 8:01 AM EDT

CRISPR Therapeutics AG Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-451.14-581.6-366.25-153.61-650.18377.66
Depreciation & Amortization
18.6919.4819.2619.8424.1717.95
Asset Writedown & Restructuring Costs
2.4796.25-2.5--
Stock-Based Compensation
68.3272.586.5781.0397.95102.39
Other Operating Activities
-23.22-23.53-38.62-16.5512.4714.11
Change in Accounts Receivable
-25175-2000.31-0.16
Change in Accounts Payable
-1.7344.89-27.28-20.255.1637.51
Change in Unearned Revenue
0.74-0.4-1.955.79-1.01-0.78
Change in Other Net Operating Assets
15.432.3910.520.8715.39-9.71
Operating Cash Flow
-369.58-345.01-142.77-260.38-495.74538.97
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-1.74-0.91-1.9-9.47-37.19-81.71
Sale (Purchase) of Intangibles
-2.47-25--2.5--
Investment in Securities
-544.21-5.89-278.58386.62-221.47-953.73
Investing Cash Flow
-548.43-31.81-280.48374.65-258.66-1,035

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Debt Issued (Repaid)
600-----
Issuance of Common Stock
427.64426.03331.9862.6638.59250.95
Other Financing Activities
-15.37-----
Financing Cash Flow
1,012426.03331.9862.6638.59250.95

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-0.050.1-0.020.07-0.08-0.01
Miscellaneous Cash Flow Adjustments
----0--
Net Cash Flow
94.2149.3-91.29177.01-715.88-245.52

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-371.33-345.93-144.68-269.85-532.93457.27
Free Cash Flow Growth
------
Free Cash Flow Margin
-2772.74%-9855.50%-387.72%-72.69%-44484.89%49.98%
Free Cash Flow Per Share
-3.92-3.85-1.72-3.41-6.865.69
Levered Free Cash Flow
-215.85-205.62-29.27-238.97-337.58284.82
Unlevered Free Cash Flow
-216.69-205.62-29.27-238.97-337.58284.82

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Change in Working Capital
14.4471.88156.27-193.5919.8526.86
SEC Filings: 10-K · 10-Q